Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome

NCT05361668 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoid Syndrome
Carcinoid
Carcinoid Tumor
Carcinoid Tumor of Ileum
Carcinoid Tumor of Cecum
Carcinoid Syndrome Diarrhea
Carcinoid Intestine Tumor
Carcinoid Tumor of Liver
Carcinoid Tumor of Pancreas

Interventions

DRUG: Randomized: 40 mg Paltusotine
DRUG: Randomized: 80 mg Paltusotine

Sponsor

Crinetics Pharmaceuticals Inc.